AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00105521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarizotan
Description: Sarizotan will be administered twice daily.
Study NCT00105521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to sarizotan will be administered twice daily.
Study NCT03741751 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized cognitive training
Description: All participants will receive computerized cognitive training for 40 min after each rTMS session.
Study NCT01878188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC-819/PEI
Description: Intravesical instillation
Study NCT01878188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: intravesical instillations
Study NCT01994538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longer therapy duration
Description: 14 days of antimicrobial treatment
Study NCT01994538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Shorter therapy duration
Description: 7 days of antimicrobial treatment
Study NCT02581371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin infusion
Description: Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
Study NCT02581371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
Study NCT02461719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYPORIN N EYE DROPS 0.05%(TJCS eye drop)
Description: 1 drop twice/day for 12 weeks to both eyes.
Study NCT02461719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: 1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
Study NCT01242033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red raspberries
Description: single serving of one, two or four cups red raspberries
Study NCT01242033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: bread controls
Description: two slices white bread alone or with 200 mg vitamin C supplement
Study NCT01242033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bread controls
Description: two slices white bread alone or with 200 mg vitamin C supplement
Study NCT00030303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant 70-kD heat-shock protein
Study NCT00948103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
Study NCT00948103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: oxygen
Study NCT02773407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Study NCT02773407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-trimoxazole
Study NCT01014663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapeutic Exercise
Description: The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
Study NCT01014663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Contact Boxing Training
Description: Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
Study NCT04360642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: singing
Description: Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
Study NCT03205540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral single-shot bilateral adductor canal blocks
Description: Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
Study NCT01074606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof Toric Intraocular Lens
Description: Implantation of the AcrySof Toric Intraocular Lens (IOL)
Study NCT05378984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: before - hypertonic saline 5%
Description: pain was induced by intramuscular injections of hypertonic saline (5%)
Study NCT00880152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: An 8-week course in mindfulness training
Study NCT05378984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: after - hypertonic saline 5%
Description: pain was induced by intramuscular injections of hypertonic saline (5%)
Study NCT03580590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Diltiazem
Description: Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
Study NCT03580590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tranexamic Acid
Description: Tranexamic acid inhibits fibrinolysis, which reduces blood loss
Study NCT03580590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study NCT03384264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
Study NCT03669055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Realization of a MRI before and after the endovascular treatment of the aortic dissection. Use of the 4D phase-contrast sequence during the MRI.
Study NCT03753919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
Study NCT03753919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
Study NCT02525757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: 1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation.
Study NCT02525757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
Study NCT04152772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
Study NCT04152772 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
Study NCT02525757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
Study NCT02525757 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
Study NCT04452864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.
Study NCT04452864 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Computerized Cognitive Training
Description: The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.
Study NCT04452864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Documentaries with delayed Computerized Cognitive Training
Description: The active control group watches documentaries for three months before starting with the CCT.
Study NCT03518125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax
Description: Other Names:~Anthrax Vaccine Adsorbed (AVA)
Study NCT03518125 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Description: Other Names:~Anthrax Vaccine Adsorbed (AVA)
Study NCT03518125 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AV7909
Description: Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
Study NCT03518125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
Study NCT03098654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood glucose and blood pressure testing
Description: Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor. Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken. Blood pressure will be assessed using a portable battery operated automatic BP cuff. The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.
Study NCT03098654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and lifestyle counseling
Description: All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed. Personalized risk reduction plans will be negotiated with the client during their scheduled visits.
Study NCT03098654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM/HTN medications as needed
Description: Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
Study NCT04114201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSI
Description: Implantation of a Total Knee Arthroplasty patient-specific instrumentation using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
Study NCT04114201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Implantation of a Total Knee Arthroplasty with conventional using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
Study NCT04490603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality experience
Description: Patients are to experice virtual reality with virtual reality experience equipment (headsets, headphones, smartphones) and virtual reality experience programs. The equipments and programs are commercialized products on the market rather than medical products.
Study NCT00811811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral neurocardiac training
Description: 6 training sessions scheduled over 8 weeks
Study NCT00811811 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic relaxation training
Description: 6 training sessions scheduled over 8 weeks
Study NCT03745729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol sustained-release capsules
Description: allopurinol sustained-release capsules (0.25g), once a day, one pill at a time
Study NCT03745729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: placebo sustained-release capsules, once a day, one pill at a time
Study NCT03518125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride injection USP, 0.9% (placebo)
Description: Other Names:~Saline Solution
Study NCT03518125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride injection USP, 0.9% (placebo)
Description: Other Names:~Saline Solution
Study NCT00582946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid
Description: Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
Study NCT04210414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo transfer
Description: Transfer of only one embryo
Study NCT00239564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 100 mg
Description: IPX054 containing 25 mg carbidopa and 100 mg levodopa
Study NCT00239564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 150 mg
Description: IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
Study NCT00239564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 200 mg
Description: CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
Study NCT00239564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 250 mg
Description: CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
Study NCT00239564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX054 300 mg
Description: CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
Study NCT04207840 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.125 mg/inhalation)
Description: Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.
Study NCT02064842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
Study NCT04207840 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Injection Auto-Injector (0.3mg/0.3mL)
Description: Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.
Study NCT04207840 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate (0.09 mg/inhalation)
Description: Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.
Study NCT02466646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klorhex® Gel, rinse and spray
Description: Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
Study NCT02466646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional IPT
Description: Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
Study NCT02466646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth IPT
Description: Initial periodontal treatment was performed in 2 sessions within 24 hours.
Study NCT04604301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celtra Quatro
Description: Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
Study NCT04671238 — intervention group
Intervention type: DEVICE
Intervention: SPECT CT
Description: SPECT/CT scan of the spine as part of a vertebroplasty
Study NCT01271998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: 200 mg, oral, once daily for 3 days.
Study NCT04508179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7HP349 Single Ascending Dose
Description: Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
Study NCT04508179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7HP349 Multiple Ascending Dose
Description: Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)
Study NCT04508179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Single Ascending Dose
Description: Part A: Placebo Capsules, Single Ascending Dose (SAD)
Study NCT04508179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Multiple Ascending Dose
Description: Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
Study NCT04508179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7HP349 Food Effect
Description: Part C: 7HP349 Capsules, Food Effect
Study NCT02098187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Below target dose MP-3180
Description: MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Study NCT02098187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: At target dose MP-3180
Description: MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Study NCT02098187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 times above target dose MP-3180
Description: MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Study NCT02098187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 times above target dose MP-3180
Description: MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Study NCT02098187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ORFM prototype
Description: The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
Study NCT02098187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol comparator
Description: Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
Study NCT03611504 — intervention group
Intervention type: DEVICE
Intervention: Hemospray®
Description: Hemospray® application
Study NCT03585296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-502
Description: Topical Solution
Study NCT01493505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386
Description: AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
Study NCT01493505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
Study NCT01493505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
Study NCT01493505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 386 Placebo
Description: AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
Study NCT01493505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 or 6 IV Q3W (6 cycles)